Percy Adrian John reported grant involving 2,500 derivative units of Evogene Ltd. at $0.00 for $0 on Sep 4, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Sep 30, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
2,500Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
2,500Direct
Trade date
Sep 4, 2026Grant
Filed
Sep 30, 2026, 8:07 AM ET26-day reporting delay
Accession
0001178913-26-004660Code A · Transaction 231520
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 26 calendar days after the transaction date.

EVGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
EVGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago +38%1d ago +38%
Returns since7d +5.1%30d −2.6%90d180d1y

Footnotes in full

F1: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date. F2: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan. F3: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date. F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.